Crossfire Oncology
Crossfire Oncology is a Netherlands-based, early-stage biotechnology company founded in 2021 in Oss, Brabant, focused on oncology. With 15 employees and no publicly disclosed products, funding, or partnerships, it operates as a small private research-stage entity.
- Company typePrivate
- Founded2021
- HeadquartersOss, Brabant, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Crossfire Oncology does
Crossfire Oncology is a Netherlands-based biotechnology company founded in 2021 and headquartered in Oss, Brabant — a region recognized as a European life sciences hub with established pharmaceutical infrastructure including MSD/Organon operations. The company name indicates an oncology-focused therapeutic or diagnostic mandate, but specific product, pipeline, technology, or scientific platform details are not available in the supplied data. The company's public website at crossfire-oncology.com is currently behind a Cloudflare verification/loading screen, preventing access to any product descriptions, scientific approach, or team information.
With 15 employees and no disclosed funding rounds, leadership team details, partnerships, customers, or regulatory milestones, Crossfire Oncology appears to operate as a small, early-stage private entity. There is no information on its revenue model, pricing strategy, go-to-market approach, or commercial traction. The complete absence of disclosed financial data, investor information, or capital raise activity in the input suggests the company may still be in a pre-seed or seed-phase operating posture, possibly reliant on founder capital, grants, or undisclosed private funding.
For investors, the data picture is limited to firmographic fundamentals: name, founding year, headcount, and location. A meaningful investment thesis would require additional diligence on the company's scientific platform, IP portfolio, management team credentials, capital structure, and pipeline — none of which are documented in the available material.
Crossfire Oncology firmographics
Firmographics- Name
- Crossfire Oncology
- Website
- https://crossfire-oncology.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Crossfire Oncology is a Netherlands-based, early-stage biotechnology company founded in 2021 in Oss, Brabant, focused on oncology. With 15 employees and no publicly disclosed products, funding, or partnerships, it operates as a small private research-stage entity.
- Ownership category
- akta.pro rank
Crossfire Oncology industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Crossfire Oncology is headquartered
LocationHeadquarters
- HQ city
- Oss, Brabant
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Crossfire Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D
Crossfire Oncology product offering
Product offeringCore offering
Based on the company name and biotech hub location, Crossfire Oncology appears to operate in the oncology/cancer therapeutics space. The company is a small (15-employee) biopharmaceutical firm founded in 2021 and headquartered in Oss, Brabant, Netherlands. No detailed product, pipeline, or service descriptions are available from the source data, as the website displays only a verification/loading screen. No specific offerings, modalities, or therapeutic targets are documented.
Differentiator
Problem solved
Functional benefit
Crossfire Oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Crossfire Oncology partnerships and signals
Strategic signalRecent moves1 record
Crossfire Oncology competitors and assessment
Company assessmentRegional players
- Byondis: Byondis is a Dutch clinical-stage biopharmaceutical company developing targeted therapeutics for cancer, also headquartered in the Oss region. Both companies operate in oncology drug development within the same Dutch biotech ecosystem, making them geographically and thematically comparable peers.
- Merus N.V. Merus is a Netherlands-based clinical-stage oncology company developing bispecific antibody therapeutics. As a Dutch oncology biotech with a similar geographic base, Merus represents a comparable peer in terms of therapeutic focus and regional ecosystem.
- Philogen: Philogen is an Italian-Swiss clinical-stage biotechnology company developing targeted oncology therapeutics using antibody and small molecule technologies. As a European oncology biotech with similar development focus, Philogen is a relevant peer for Crossfire Oncology.
Broad incumbents
- Astellas Pharma: Astellas is a major Japanese pharmaceutical company with a significant oncology franchise including antibody-drug conjugates and targeted therapies. As a large pharma with oncology as a core therapeutic area, Astellas represents a broad incumbent peer and potential strategic acquirer.
Emerging players
- CatalYm: CatalYm is a German clinical-stage immuno-oncology company developing neutralizing antibodies targeting GDF-15. As a European small-cap oncology biotech, CatalYm is a comparable emerging peer in early-stage oncology drug development.
- Monopar Therapeutics: Monopar is a clinical-stage oncology biotech developing targeted therapeutics. As a small-cap oncology company at a similar stage, Monopar represents a comparable emerging peer in oncology drug development.
Direct peers
- Genmab: Genmab is a Denmark-based international biotechnology company specializing in antibody therapeutics for cancer. Both companies operate in oncology biologics development, making Genmab a direct peer in therapeutic area and technology platform.
- ADC Therapeutics: ADC Therapeutics is a commercial-stage biotechnology company developing antibody-drug conjugates for hematological cancers and solid tumors. As a focused oncology therapeutics company, it represents a direct peer in oncology drug development.
- Innovent Biologics: Innovent is a Chinese biopharmaceutical company developing innovative oncology biologics including monoclonal antibodies and bispecifics. As a developer of oncology therapeutics with a similar therapeutic focus, Innovent is a direct peer in oncology drug development.
- Sun Pharma Advanced Research Company: SPARC is a pharmaceutical R&D company developing innovative therapies including oncology treatments. As a research-focused oncology drug developer, SPARC represents a comparable peer in early-stage therapeutic development.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key highlights3 records
Customer concentration
Crossfire Oncology social profiles
Digital presenceCrossfire Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Crossfire Oncology leadership team
Management profileNumber of profiles
Crossfire Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Crossfire Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Crossfire Oncology
What does Crossfire Oncology do?
Based on the company name and biotech hub location, Crossfire Oncology appears to operate in the oncology/cancer therapeutics space. The company is a small (15-employee) biopharmaceutical firm founded in 2021 and headquartered in Oss, Brabant, Netherlands. No detailed product, pipeline, or service descriptions are available from the source data, as the website displays only a verification/loading screen. No specific offerings, modalities, or therapeutic targets are documented.
When was Crossfire Oncology founded?
Crossfire Oncology was founded in 2021. It employs 11 to 50 people.
Where is Crossfire Oncology based?
Crossfire Oncology is headquartered in Oss, Brabant, Netherlands, in the Europe region.
Who are Crossfire Oncology's main competitors?
Regional players on record are Byondis, Merus N.V. and Philogen. Astellas Pharma is listed as a broad incumbent. Emerging players are CatalYm and Monopar Therapeutics. Direct peers are Genmab, ADC Therapeutics, Innovent Biologics and Sun Pharma Advanced Research Company.
Does Crossfire Oncology have an API?
No public API is recorded for Crossfire Oncology.
What industry is Crossfire Oncology in?
Crossfire Oncology's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.